One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study

Abstract

The clinical safety of the XIENCE V EECSS stent observed at six months was sustained at one year. There were no additional thrombotic or MACE events in the EECSS group. Although not a primary endpoint, there was a significant difference in MACE favouring the EECSS compared to PECSS (2.7% versus 9.2%, P=0.04).